News

Absci's ABS-201 posts early phase 1 safety and long half-life, while new data show prolactin-receptor blockade may revive hair growth in AGA.

The European Commission greenlights upadacitinib for severe alopecia areata, with phase 3 data showing rapid scalp, brow and lash regrowth; US decision still pending.

Conexeu is advancing its ECM-regenerating tissue tech, targeting wound care via FDA 510(k) and eyeing aesthetics, reconstruction, and beyond.

Karen McGuire, PhD, CEO and co-founder of BioMendics, explains what fast track status means for the investigational treatment and details the drug's mechanism of action in EBS.

This review of the latest dermatological studies includes insights on fibromyalgia in rosacea patients, isotretinoin use and suicidality in adolescents, patient-centered teledermatology, and more.

Leon Kircik, MD, discusses zasocitinib scalp psoriasis clearance rates from the LATITUDE 1 and 2 trials presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.

AAD guidelines strongly recommend roflumilast, ruxolitinib, and tapinarof, expanding steroid-sparing options for pediatric atopic dermatitis.

Explore the top dermatology conferences and meetings happening this month and let us know which ones you'll be attending!

FDA reviews phase 3 results and expanded BOTOX Cosmetic use for masseter prominence and nonsurgical jawline contouring, potentially becoming the first neurotoxin approved in the US for this indication.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

Catch up on the biggest clinical updates, expert insights, and exclusive interviews from Elevate-Derm Summer 2026 in San Diego, California.

In this edition of The Practice Playbook, learn incident-to rules, Mohs coding limits, NPI liability, and how audits and whistleblowers trigger FCA cases.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Catch Up on Coverage From Day 5 of the 3rd Annual Elevate-Derm Summer Conference

As we wrap up UV Safety Awareness Month, Kathleen Suozzi, MD, explains warning signs of sun damage, sunscreen myths, and new year-round protection tools—plus the newly FDA-approved bemotrizinol.

Catch Up on Coverage From Day 4 of the 3rd Annual Elevate-Derm Summer Conference

Catch Up on Coverage From Day 3 of the 3rd Annual Elevate-Derm Summer Conference

Faculty at Elevate-Derm Summer 2026 discussed the expanding role of oral JAK inhibitors in pediatric dermatology, emphasizing earlier intervention, individualized patient selection, safety monitoring, and family-centered counseling.

Advances in vitiligo, hidradenitis suppurativa, and hair loss were among the key trends Chantel Hillstead, APRN, said APPs should watch.

Lisa Swanson, MD, discussed strategies for counseling patients on JAK inhibitor safety and where she sees the drug class expanding next in a recent Dermatology Times interview.

Learn more about the in-depth topics covered in the July 2026 digital issue of Dermatology Times.

In July's letter from the editor in chief, Christopher Bunick, MD, PhD, breaks down why dermatology clinicians should be skilled in wound care.

Oyetewa Asempa, MD, discussed the importance of scalp examination, trichoscopy, and culturally informed communication when evaluating patients with hair loss during a recent Dermatology Times interview

Victoria Garcia Albea, NP, discussed safety monitoring, patient selection, and laboratory screening considerations for oral JAK inhibitors at Elevate-Derm summer 2026

Catch Up on Coverage From Day 2 of the 3rd Annual Elevate-Derm Summer Conference

At Elevate Derm, Lisa Swanson, MD, discussed earlier oral JAK inhibitor use for alopecia areata and selecting appropriate patients.

Two phase 3 trials of Pfizer's ritlecitinib met co-primary end points for facial and total repigmentation in nonsegmental vitiligo at week 52, prompting plans for global regulatory filings.

In this Cosmetics Conundrums column, learn why the cosmeceutical vehicle drives 80% of skin care results, shaping feel, film, and active delivery for visible benefits.

RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.